Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

The Finviz API:   Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now
Market News Market Pulse Stocks News ETF News Crypto News

Lexeo Therapeutics

Contributing Author

Recent Articles by Lexeo Therapeutics

Oct-08
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference LXEO GlobeNewswire
Oct-01
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS) LXEO +7.10% GlobeNewswire
Sep-23
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum LXEO -13.51% GlobeNewswire
Sep-22
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia LXEO GlobeNewswire
Sep-02
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September LXEO GlobeNewswire
Aug-12
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights LXEO GlobeNewswire
Aug-05
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy LXEO GlobeNewswire
Jun-17
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia LXEO GlobeNewswire
Jun-15
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia LXEO +6.41% GlobeNewswire
May-19
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference LXEO GlobeNewswire
May-11
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights LXEO GlobeNewswire
Apr-27
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting LXEO GlobeNewswire
Mar-30
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights LXEO LXEO +8.92% GlobeNewswire
Mar-03
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference LXEO GlobeNewswire
Feb-05
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February LXEO -5.23% GlobeNewswire
Jan-27
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics LXEO GlobeNewswire
Jan-12
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy LXEO -22.96% GlobeNewswire
Jan-08
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy LXEO -5.49% GlobeNewswire
Dec-22
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference LXEO GlobeNewswire
Dec-04
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum LXEO GlobeNewswire
Nov-05
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Oct-20
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering LXEO GlobeNewswire
Oct-16
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement LXEO +9.24% GlobeNewswire
Oct-16
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants LXEO LXEO +9.24% GlobeNewswire
Oct-07
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy LXEO +28.90% GlobeNewswire
Aug-14
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Jul-07
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia LXEO GlobeNewswire
Jun-24
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics LXEO +6.31% GlobeNewswire
May-27
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases LXEO GlobeNewswire
May-12
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
May-01
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting LXEO +19.85% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)